Continuous dose of nitroglycerin increases severity of heart attacks, study shows
When given for hours as a continuous dose, the heart medication nitroglycerin backfires — increasing the severity of subsequent heart attacks, according to a study of the compound in rats by researchers at the Stanford University School of Medicine.
“Basically it’s a cautionary tale,” said professor of chemical and systems biology Daria Mochly-Rosen, PhD, senior author of the study published Nov. 2 in Science Translational Medicine. “Here is a practice in medicine used for over 100 years. Nitroglycerin is so old that a proper clinical trial has never been formally done. Our study says it’s time for cardiologists to examine the value of nitroglycerin treatment that extends for hours at a time.”
Congratulations to Joanna Wysocka, one of four scientists at the Stanford University School of Medicine that were awarded a total of $5.7 million in new funding from state stem cell agency
Four scientists at the Stanford University School of Medicine have been awarded a total of $5.7 million by the state stem cell agency to investigate the basic mechanisms of stem cell biology, cellular plasticity and differentiation. The awards, which were announced recently, were part of $37.7 million distributed to 27 investigators from nine institutions by the California Institute for Regenerative Medicine in the third round of the agency’s Basic Biology Awards.
Congratulations to Joshua Elias for being featured in "Inside Stanford Medicine"as one of this year’s Innovation Awardees from the Damon Runyon Foundation (February 2011)
The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high risk/high reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.
The National Research Council Ranks Stanford CSB #1
The National Research Council released the Data-Based Assessment of Research-Doctorate Programs on September 28, 2010. The report consists of a descriptive volume, and a comprehensive data table in Excel containing data on characteristics and ranges of rankings for over 5000 programs in 62 fields at 212 institutions.
Out of 116 pharmacology-related programs, Stanford University was rated #1 by one overall metric (S-rankings), and was one of nine tightly-clustered schools at the top by the other overall metric (R-rankings). Stanford’s greatest strength was seen to be in the area of research activity.
Every 10-15 years the National Research Council rates PhD programs in the US. They recently published this year's results, which were based on information collected in 2006-2007. The factors that weighed into the ratings included students' GRE scores, faculty pubs and impact factors, median time to degree, and the presence or absence of various program-related resources and requirements (e.g. an active grad students association and formal ethics training, which Stanford has, and formal writing instruction, which Stanford does not have).
The last time around (1995) Stanford was ranked #27.
A unique chromatin signature uncovers early developmental enhancers in humans
Cell-fate transitions involve the integration of genomic information encoded by regulatory elements, such as enhancers, with the cellular environment.
Internal Staff Login